{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:50:23Z","timestamp":1780372223592,"version":"3.54.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kyowa Kirin Australia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although hearing impairment is often listed as a nonskeletal complication of X-linked hypophosphatemia (XLH), the prevalence, etiology, pathology, and natural history are poorly described. This review aims to summarize existing literature with a view to guide the clinical management of hearing impairment in XLH. The review was conducted by 2 researchers independently. Four databases (PubMed\/Medline, EMBASE, Web of Science, and Cochrane Library) were searched between January 1, 2000 and July 31, 2024, with keywords related to \u201cX-linked hypophosphataemic rickets\u201d and \u201chearing loss\u201d including synonyms. Identified records were screened for inclusion and exclusion criteria. Human and animal studies were included. Out of 82 records found excluding duplicates, 12 studies met the final criteria and were reviewed. Studies described both conductive and sensorineural hearing loss in 13%-76% of adults with XLH, with sensorineural hearing loss more commonly reported, with impairment developing in adulthood, affecting high and low frequencies, and may be fluctuating. Evidence suggests that endolymphatic hydrops (ELH) may be a major underlying cause of hearing loss in XLH. Individuals with XLH have generalized osteosclerosis with petrous bone thickening and narrowing of the auditory meatus. No studies have looked at burosumab, a monoclonal antibody that inhibits FGF23, and its effect on the development of hearing loss in individuals with XLH. Animal studies of XLH mouse models (Hyp and Gy) describe both conductive and sensorineural hearing impairment. Mouse models demonstrate high Auditory Brainstem Response (ABR) thresholds and signs of osteomalacia of auditory ossicles and ELH. In conclusion, there is an association between hearing loss in XLH and, most commonly, adult-onset sensorineural hearing loss. Pathogenesis of hearing loss in XLH is incompletely understood, but possible contributing factors include thickening of the temporal bones, osteomalacia of the auditory ossicles, and development of ELH. There is currently no evidence that treatment with conventional therapy or burosumab reduces the risk or severity of hearing impairment.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf062","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T07:45:50Z","timestamp":1744962350000},"page":"v14-v29","source":"Crossref","is-referenced-by-count":2,"title":["Hearing impairment in X-linked hypophosphatemia: a review"],"prefix":"10.1093","volume":"9","author":[{"given":"Seongeun","family":"Oh","sequence":"first","affiliation":[{"name":"Melbourne Medical School, University of Melbourne , Parkville, VIC 3010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L","family":"Sandy","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology and Diabetes, The Children\u2019s Hospital at Westmead , Westmead, NSW 2145 ,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of Sydney , Camperdown, NSW 2006 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig F","family":"Munns","sequence":"additional","affiliation":[{"name":"Child Health Research Centre, Faculty of Medicine, The University of Queensland , Brisbane, QLD ,","place":["Australia"]},{"name":"Department of Endocrinology and Diabetes, Queensland Children\u2019s Hospital , Brisbane, QLD ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"Simm","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University of Melbourne , Melbourne, VIC 3010 ,","place":["Australia"]},{"name":"Department of Endocrinology and Diabetes, Royal Children\u2019s Hospital , Melbourne, VIC 3052 ,","place":["Australia"]},{"name":"Centre for Hormone Research, Murdoch Children\u2019s Research Institute , Melbourne, VIC 3002 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aris","family":"Siafarikas","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Perth Children\u2019s Hospital , Perth, WA 6009 ,","place":["Australia"]},{"name":"Medical School, Paediatrics, University of Western Australia , Perth, WA 6009 ,","place":["Australia"]},{"name":"Institute for Health Research, University of Notre Dame , Fremantle, WA 6160 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Collins","sequence":"additional","affiliation":[{"name":"Western Health , Footscray, VIC 3001 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie-Lee","family":"Wall","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology and Diabetes, The Children\u2019s Hospital at Westmead , Westmead, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E","family":"Craig","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology and Diabetes, The Children\u2019s Hospital at Westmead , Westmead, NSW 2145 ,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of Sydney , Camperdown, NSW 2006 ,","place":["Australia"]},{"name":"Paediatrics & Child Health, School of Clinical Medicine, University of New South Wales , Sydney, NSW 2031 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine P","family":"Rodda","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University of Melbourne , Melbourne, VIC 3010 ,","place":["Australia"]},{"name":"Centre for Hormone Research, Murdoch Children\u2019s Research Institute , Melbourne, VIC 3002 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Biggin","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology and Diabetes, The Children\u2019s Hospital at Westmead , Westmead, NSW 2145 ,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of Sydney , Camperdown, NSW 2006 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"issue":"1","key":"2025122308354420200_ref1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"2025122308354420200_ref2","doi-asserted-by":"publisher","first-page":"688309","DOI":"10.3389\/fendo.2021.688309","article-title":"X-linked hypophosphatemic rickets: multisystemic disorder in children requiring multidisciplinary management","volume":"12","author":"Baroncelli","year":"2021","journal-title":"Front Endocrinol"},{"issue":"12","key":"2025122308354420200_ref3","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.tem.2012.07.002","article-title":"Fibroblast growth factor 23: state of the field and future directions","volume":"23","author":"Bhattacharyya","year":"2012","journal-title":"Trends Endocrinol Metab"},{"issue":"7","key":"2025122308354420200_ref4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"2025122308354420200_ref5","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/jpc.15976","article-title":"Clinical practice guidelines for paediatric X-linked hypophosphataemia in the era of burosumab","volume":"58","author":"Sandy","year":"2022","journal-title":"J Paediatr Child Health"},{"issue":"2","key":"2025122308354420200_ref6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.7326\/0003-4819-100-2-230","article-title":"Impaired hearing in X-linked hypophosphataemic (vitamin-D-resistant) osteomalacia","volume":"100","author":"Davies","year":"1984","journal-title":"Ann Intern Med"},{"issue":"1\u20132","key":"2025122308354420200_ref7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/00016488509108581","article-title":"Electrocochleographic changes in the hearing loss associated with X-linked hypophosphataemic osteomalacia","volume":"100","author":"O'Malley","year":"1985","journal-title":"Acta Otolaryngol"},{"issue":"5","key":"2025122308354420200_ref8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S0009-9260(88)80224-1","article-title":"The petrous temporal bone and deafness in X-linked hypophosphataemic osteomalacia","volume":"39","author":"O'Malley","year":"1988","journal-title":"Clin Radiol"},{"issue":"4","key":"2025122308354420200_ref9","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/ajmg.1320270434","article-title":"Audiometric evidence for two forms of X-linked hypophosphatemia in humans, apparent counterparts of Hyp and Gy mutations in mouse","volume":"27","author":"Boneh","year":"1987","journal-title":"Am J Med Genet"},{"key":"2025122308354420200_ref10","first-page":"157","volume-title":"Handbook of Clinical Neurology","author":"Davies","year":"2016"},{"issue":"8","key":"2025122308354420200_ref11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s003359900499","article-title":"Mutation watch: PEX PLUS? Gene(s) for X-linked hypophosphatemia and deafness","volume":"8","author":"Meisler","year":"1997","journal-title":"Mamm Genome"},{"issue":"3","key":"2025122308354420200_ref12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1530\/JOE-11-0193","article-title":"Mouse models for inherited endocrine and metabolic disorders","volume":"211","author":"Piret","year":"2011","journal-title":"J Endocrinol"},{"issue":"12","key":"2025122308354420200_ref13","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/jbmr.4443","article-title":"Conductive hearing loss in the Hyp mouse model of X-linked hypophosphatemia is accompanied by hypomineralization of the auditory ossicles","volume":"36","author":"Delsmann","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025122308354420200_ref14","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1111\/coa.13825","article-title":"Characterization of otologic involvement in patients with X-linked hypophosphatemia","volume":"46","author":"Ivanovic-Zuvic","year":"2021","journal-title":"Clin Otolaryngol"},{"issue":"9","key":"2025122308354420200_ref15","doi-asserted-by":"publisher","first-page":"E3682","DOI":"10.1210\/clinem\/dgab282","article-title":"Incidence of complications in 25 adult patients with X-linked hypophosphatemia","volume":"106","author":"Kato","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025122308354420200_ref16","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","article-title":"Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations","volume":"41","author":"Chesher","year":"2018","journal-title":"J Inherit Metab Dis"},{"issue":"10","key":"2025122308354420200_ref17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00431-004-1504-z","article-title":"Hearing impairment in familial X-linked hypophosphatemic rickets","volume":"163","author":"Fishman","year":"2004","journal-title":"Eur J Pediatr"},{"issue":"12","key":"2025122308354420200_ref18","doi-asserted-by":"publisher","first-page":"e10692","DOI":"10.1002\/jbm4.10692","article-title":"X-linked hypophosphatemia caused by the prevailing north American PHEX variant c.*231A&gt;G; exon 13-15 duplication is often misdiagnosed as ankylosing spondylitis and manifests in both men and women","volume":"6","author":"Dahir","year":"2022","journal-title":"JBMR Plus"},{"issue":"1","key":"2025122308354420200_ref19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1515\/hsz-2014-0187","article-title":"Identification of a novel PHEX mutation in a Chinese family with X-linked hypophosphatemic rickets using exome sequencing","volume":"396","author":"Yuan","year":"2015","journal-title":"Biol Chem"},{"issue":"1","key":"2025122308354420200_ref20","first-page":"73","article-title":"X-linked hypophosphatemia in polish patients. 2. Analysis of clinical features and genotype-phenotype correlation","volume":"42","author":"Popowska","year":"2001","journal-title":"J Appl Genet"},{"issue":"1","key":"2025122308354420200_ref21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1017\/S0022215107001636","article-title":"Hearing loss and fluctuating hearing levels in X-linked hypophosphataemic osteomalacia","volume":"123","author":"Pantel","year":"2009","journal-title":"J Laryngol Otol"},{"issue":"1","key":"2025122308354420200_ref22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.amjoto.2016.09.014","article-title":"Treatment of ear and bone disease in the Phex mouse mutant with dietary supplementation","volume":"38","author":"Wick","year":"2017","journal-title":"Am J Otolaryngol"},{"issue":"1\u20132","key":"2025122308354420200_ref23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.heares.2008.01.002","article-title":"A mouse model with postnatal endolymphatic hydrops and hearing loss","volume":"237","author":"Megerian","year":"2008","journal-title":"Hear Res"},{"issue":"3","key":"2025122308354420200_ref24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00335-003-2310-z","article-title":"New intragenic deletions in the Phex gene clarify X-linked hypophosphatemia-related abnormalities in mice","volume":"15","author":"Lorenz-Depiereux","year":"2004","journal-title":"Mamm Genome"},{"issue":"9","key":"2025122308354420200_ref25","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a033258","article-title":"The epidemiology of deafness","volume":"9","author":"Sheffield","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"2025122308354420200_ref26","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1186\/s12889-024-18426-9","article-title":"Trends in prevalence of hearing loss in adults in the USA 1999-2018: a cross-sectional study","volume":"24","author":"Mo","year":"2024","journal-title":"BMC Public Health"},{"issue":"10278","key":"2025122308354420200_ref27","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/S0140-6736(21)00516-X","article-title":"Hearing loss prevalence and years lived with disability, 1990-2019: findings from the global burden of disease study 2019","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"2025122308354420200_ref28","doi-asserted-by":"publisher","first-page":"1211426","DOI":"10.3389\/fendo.2023.1211426","article-title":"Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives","volume":"14","author":"Seefried","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2025122308354420200_ref29","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1177\/002215540305101109","article-title":"Network organization of interstitial connective tissue cells in the human endolymphatic duct","volume":"51","author":"Hultg\u00e5rd-Ekwall","year":"2003","journal-title":"J Histochem Cytochem"},{"issue":"3 Pt 1","key":"2025122308354420200_ref30","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/000348940211100308","article-title":"Vascular occlusion in the endolymphatic sac in Meniere's disease","volume":"111","author":"Friberg","year":"2002","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"9","key":"2025122308354420200_ref31","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1097\/MAO.0b013e31826dba83","article-title":"Oral steroid treatment for hearing improvement in M\u00e9ni\u00e8re's disease and endolymphatic hydrops","volume":"33","author":"Fisher","year":"2012","journal-title":"Otol Neurotol"},{"issue":"5","key":"2025122308354420200_ref32","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1097\/01.mao.0000185057.81962.51","article-title":"Oral administration of prednisone to control refractory vertigo in M\u00e9ni\u00e8re's disease: a pilot study","volume":"26","author":"Morales-Luckie","year":"2005","journal-title":"Otol Neurotol"},{"issue":"2","key":"2025122308354420200_ref33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.otohns.2005.05.010","article-title":"Dexamethasone inner ear perfusion by Intratympanic injection in unilateral M\u00e9ni\u00e8re\u2019s disease: a two-year prospective, placebo-controlled, double-blind, randomized trial","volume":"133","author":"Gardu\u00f1o-Anaya","year":"2005","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"2025122308354420200_ref34","doi-asserted-by":"publisher","first-page":"102817","DOI":"10.1016\/j.amjoto.2020.102817","article-title":"Meniere's disease: medical management, rationale for vestibular preservation and suggested protocol in medical failure","volume":"42","author":"Christopher","year":"2021","journal-title":"Am J Otolaryngol"},{"issue":"11","key":"2025122308354420200_ref35","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1097\/00005537-199811000-00017","article-title":"Hearing results of intratympanic steroid treatment of endolymphatic hydrops","volume":"108","author":"Arriaga","year":"1998","journal-title":"Laryngoscope"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/Supplement_5\/v14\/66116589\/ziaf062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/Supplement_5\/v14\/66116589\/ziaf062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:35:49Z","timestamp":1766496949000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/9\/Supplement_5\/v14\/8402937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"journal-issue":{"issue":"Supplement_5","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf062","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,12]]}}}